Tesmilifene Free Base | CAS# 98774-23-3 (free base) | small-molecule antineoplastic drug and chemopotentiator

MedKoo Cat#: 413541 | Name: Tesmilifene Free Base

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Tesmilifene Free Base, also known as N, N-diethyl-2-ethanamine, is a small-molecule antineoplastic drug and chemopotentiator that was under development by YM BioSciences for the treatment of breast cancer in the 2000s but was never marketed.

Chemical Structure

Tesmilifene Free Base

CAS#98774-23-3 (free base)

Theoretical Analysis

MedKoo Cat#: 413541

Name: Tesmilifene Free Base

CAS#: 98774-23-3 (free base)

Chemical Formula: C19H25NO

Exact Mass: 283.1936

Molecular Weight: 283.42

Elemental Analysis: C, 80.52; H, 8.89; N, 4.94; O, 5.65

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

98774-23-3 (free base) 92981-78-7 (HCl)

Synonym

Tesmilifene Free Base; YMB-1002; YMB 1002; YMB1002

IUPAC/Chemical Name

Ethanamine, N,N-diethyl-2-(4-(phenylmethyl)phenoxy)-

InChi Key

NFIXBCVWIPOYCD-UHFFFAOYSA-N

InChi Code

InChI=1S/C19H25NO/c1-3-20(4-2)14-15-21-19-12-10-18(11-13-19)16-17-8-6-5-7-9-17/h5-13H,3-4,14-16H2,1-2H3

SMILES Code

CCN(CC)CCOC1=CC=C(CC2=CC=CC=C2)C=C1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 283.42 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Walter FR, Veszelka S, Pásztói M, Péterfi ZA, Tóth A, Rákhely G, Cervenak L, Ábrahám CS, Deli MA. Tesmilifene modifies brain endothelial functions and opens the blood-brain/blood-glioma barrier. J Neurochem. 2015 Sep;134(6):1040-54. doi: 10.1111/jnc.13207. Epub 2015 Jul 23. PMID: 26112237. 2: Choi YH, Suh JH, Lee JH, Cho IH, Lee MG. Effects of tesmilifene, a substrate of CYP3A and an inhibitor of P-glycoprotein, on the pharmacokinetics of intravenous and oral docetaxel in rats. J Pharm Pharmacol. 2010 Aug;62(8):1084-8. doi: 10.1111/j.2042-7158.2010.01129.x. PMID: 20663044. 3: Ferguson PJ, Brisson AR, Koropatnick J, Vincent MD. Enhancement of cytotoxicity of natural product drugs against multidrug resistant variant cell lines of human head and neck squamous cell carcinoma and breast carcinoma by tesmilifene. Cancer Lett. 2009 Feb 18;274(2):279-89. doi: 10.1016/j.canlet.2008.09.021. Epub 2008 Nov 4. PMID: 18986763. 4: Vincent M. Tesmilifene may enhance breast cancer chemotherapy by killing a clone of aggressive, multi-drug resistant cells through its action on the p-glycoprotein pump. Med Hypotheses. 2006;66(4):715-31. doi: 10.1016/j.mehy.2005.11.005. Epub 2006 Jan 18. PMID: 16413681. 5: Liu J, Tu D, Dancey J, Reyno L, Pritchard KI, Pater J, Seymour LK. Quality of life analyses in a clinical trial of DPPE (tesmilifene) plus doxorubicin versus doxorubicin in patients with advanced or metastatic breast cancer: NCIC CTG Trial MA.19. Breast Cancer Res Treat. 2006 Dec;100(3):263-71. doi: 10.1007/s10549-006-9257-1. Epub 2006 Jul 6. PMID: 16823511. 6: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2004 Apr;26(3):211-44. PMID: 15148527. 7: Deng T, Liu JC, Pritchard KI, Eisen A, Zacksenhaus E. Preferential killing of breast tumor initiating cells by N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine/tesmilifene. Clin Cancer Res. 2009 Jan 1;15(1):119-30. doi: 10.1158/1078-0432.CCR-08-1708. PMID: 19118039. 8: Xu FY, Queen G, Brandes L, Hatch GM. The phospholipidosis-lnducing potential of the chemopotentiating drug, N,N-Diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine (DPPE, tesmilifene) correlates with its stimulation of phosphatidylserine synthesis and exposure on the plasma membrane in MCF-7 breast cancer cells. Proc West Pharmacol Soc. 2007;50:61-3. PMID: 18605231. 9: Brandes LJ. N,N-diethyl-2-[4-(phenylmethyl) phenoxy] ethanamine (DPPE; tesmilifene), a chemopotentiating agent with hormetic effects on DNA synthesis in vitro, may improve survival in patients with metastatic breast cancer. Hum Exp Toxicol. 2008 Feb;27(2):143-7. doi: 10.1177/0960327108090751. PMID: 18480139. 10: Prud'homme GJ. Cancer stem cells and novel targets for antitumor strategies. Curr Pharm Des. 2012;18(19):2838-49. doi: 10.2174/138161212800626120. PMID: 22390767.